Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

#8482;; the timing of the announcement of clinical results and potential regulatory filings by Baxter Healthcare for BAX 855; the timing of availability of topline overall survival data for the NKTR-102 BEACON study; and the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, (i) our drug candidates and those of our collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in previous preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the commercial launch of our drug candidates may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) acceptance, review and app
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... DUBLIN , Nov. 26, 2014  Perrigo Company ... leading global provider of "Quality Affordable Healthcare Products®," today ... offering relating to the sale of 6,809,210 ordinary shares ... including the full exercise of the option to purchase ... Morgan Securities LLC and Barclays Capital Inc., as representatives ...
(Date:11/26/2014)... , Nov. 26, 2014   Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines targeting ... Ph.D., President and CEO of Regulus, will present a ... Jaffray Healthcare Conference at the New York Palace Hotel ... The presentation will be webcast at the time of ...
(Date:11/26/2014)... Scott Steiger lives in St. ... an engineer for the past 20 years, he,s traveled extensively and ... He,s been to six of the seven continents. Travel is a ... http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 So ... pretty good idea of what,s required. His latest creation ...
Breaking Medicine Technology:Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Steiger Has Created the First Pill Case Specifically Designed For Travel 2
... by experts to be important for cervical cancer ... data from an,extended follow-up study show that GlaxoSmithKline ... generates sustained high levels of,neutralizing antibodies against the ... up to 6.4 years. This is the longest,duration ...
... American Society of Hypertension,s Twenty-Third ... Annual Scientific Meeting - A cumulative ... a regimen of BENICAR(R) (olmesartan medoxomil), and BENICAR HCT(R) (olmesartan ... normotension (< 120/80 mm Hg) (placebo:1.4%)., - Eight out of ...
Cached Medicine Technology:CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 4CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 5CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 2New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 3New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 4New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 5New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 7
(Date:11/28/2014)... November 28, 2014 Not only is ... products free of petroleum, parabens and other cancer-causing agents, ... fund research, education and awareness programs that help in ... and owners have raised an incredible, record-breaking contribution of ... Cure, sales of the Sweet Red Rose Whip Moisturizer ...
(Date:11/28/2014)... November 28, 2014 Mabel’s Labels ... kids lose® and an award-winning company established by four ... Cynthia Esp, and Tricia Mumby have been honored with ... recognized with the PROFIT Award for Excellence in Entrepreneurship. ... Esp, and Tricia Mumby) accepted the award on behalf ...
(Date:11/28/2014)... 28, 2014 Lice Troopers Lice Removal Service ... its in-home head lice service for moms in Miami-Dade County. ... of Coral Gables on Pone De-leon Blvd in Miami. ... that service Miami-Dade & Broward. Lice Troopers is the ... Florida which has been treating families for several years. , ...
(Date:11/28/2014)... November 28, 2014 Schools like ... of providing quality commercial playground equipment to its ... APCPLAY© to supply an affordable play structure at ... , Centra provides comprehensive programs for children ... emotional support services. They have served the ...
(Date:11/28/2014)... Most of the people attending a presentation by Ken Farmer ... Woods retirement community found out the “prized” possessions they ... have made the cut to be on an “Antiques Roadshow” ... and folk art and his appearances on the PBS program ... and selling antiques. Broadly speaking the antiques market is ...
Breaking Medicine News(10 mins):Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:Lice Troopers Lice Removal Service Expands in Miami-Dade 2Health News:Centra Rivermont (VA) Provides School Playground Equipment from APCPLAY© for Special Needs Students 2Health News:Centra Rivermont (VA) Provides School Playground Equipment from APCPLAY© for Special Needs Students 3Health News:Antiques Appraiser Sheds Light on "Treasures" 2
... study published today in the Archives of Internal ... health information technology (health IT) to its full potential ... care costs. The study, supported by The Commonwealth Fund ... of Medicine at Parkland Health & Hospital System and ...
... spend any timeeven a few monthswithout health care coverage, according ... of Medical Care Research and Review . , For ... there is a 2.8 percentage point decrease in the likelihood ... Partial-Year Insurance Coverage and the Health Care Utilization of Children. ...
... $80.8 Million and EPS Increased to $1.12-- Board of ... One Million SharesSCOTTSDALE , Ariz., Jan. 26 Matrixx ... company that develops and markets over-the-counter products that provide ... financial results for its fiscal 2009 third quarter and ...
... workshop to investigate increase in Acanthamoeba keratitis and to ... products and protect against infectionsST. LOUIS, Jan. 26 ... of contact lenses and lens care products for consumers, ... co-sponsored a workshop last week with the U.S. Food ...
... vote by members -- and challenge Washington, D.C. officials ... Calif., Jan. 26 On Friday, SEIU officials in ... support the undemocratic transfer of 65,000 nursing home and ... face an immediate takeover and the expulsion of more ...
... positive, third of popular sweetened products showed traces , , ... tested samples of commercial high-fructose corn syrup (HFCS) contained ... of 55 popular brand-name food and beverage products where ... to two new U.S. studies. , HFCS has replaced ...
Cached Medicine News:Health News:Physician use of HIT in hospitals linked to fewer deaths and complications, lower costs 2Health News:Physician use of HIT in hospitals linked to fewer deaths and complications, lower costs 3Health News:New study: Short coverage lapses limit children's access to health care services 2Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 2Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 3Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 4Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 5Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 6Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 7Health News:AOA Doctors of Optometry Partner With FDA and Other Industry Leaders to Develop New Measures to Better Protect Contact Lens Wearers 2Health News:AOA Doctors of Optometry Partner With FDA and Other Industry Leaders to Develop New Measures to Better Protect Contact Lens Wearers 3Health News:AOA Doctors of Optometry Partner With FDA and Other Industry Leaders to Develop New Measures to Better Protect Contact Lens Wearers 4Health News:AOA Doctors of Optometry Partner With FDA and Other Industry Leaders to Develop New Measures to Better Protect Contact Lens Wearers 5Health News:Healthcare Workers Answer SEIU Ultimatum 2Health News:Study Finds High-Fructose Corn Syrup Contains Mercury 2
... WideBiter Punch series facilitates fast and effective ... smooth, anatomically shaped meniscal rim. The flat, ... to access even the tightest joint spaces. ... Inc., 20 years of engineering experience in ...
... fast and effective resection of meniscal tears ... rim. The flat, crescent-shaped tip has an ... tightest joint spaces. Made in the U.S. ... engineering experience in arthroscopy hand instrument design ...
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
Medicine Products: